LINKEDIN

A LIFE-SCIENCE CONSULTANCY

Accelerating Access

To Innovative Healthcare Technologies

Embracing the Cause

Deliberate

Communication

Leadership for Change

Welcome to Syenza

Innovative healthcare technologies improve health, when accessible!

A future of vibrant health awaits, but access barriers are complex and seem insurmountable. Syenza  advances access with our HEOR, Global Market Access,  and Dynamic Intelligence scientific services for Pharmaceutical, Medtech, and Biotech businesses. Simply put, value science is how we accelerate access to innovations that improve health.

Our Services

Our vision to accelerate access is propelled by three, distinct service dimensions – HEOR, Global Market Access, and Dynamic Intelligence Services. Inspiration, specialization and passion define what we do to
support our clients in the Pharma, Medtech, and Biotech industry.

What do our clients value most about working with Syenza?

Syenza promptly identifies our needs and delivered appropriate services
1
Syenza is dependable
1
Syenza accurately executes activities at the highest standard
1
Syenza provides individualised and culturally intelligent services
1

We've come a long way

Laozi said a journey of a thousand miles begins with a single step. Our first step started in
January 2008 and along the way we’ve acquired the experience and expertise to
accelerate access to innovative healthcare technologies.

OCTOBER 2022
We publish the world's first budget-impact analysis on a novel medical device with economic benefits for payors.
DECEMBER 2021
We further expand the team, and publish the first budget-impact analysis of its kind in the Middle East.
NOVEMBER 2022
Results of our cost-effectiveness analysis on novel treatments continue to go global influencing major stakeholders.
APRIL 2018
We introduce the first fully online applied pharmacoeconomic course attended by hundreds in SSA and MENA.
SEPTEMBER 2016
Our team expands to support a new Client Charter and clients include Top Pharma and MedTech companies.
JANUARY 2008
Our Founder starts consulting at the WHO and Harvard Medical School after receiving his Ph.D. at Northeastern University.
JUNE 2017
Our health economic projects cover various cancers, CVD, rheumatoid arthritis, epilepsy, multiple sclerosis, & HIV/AIDS.
JUNE 2015
We strengthen our market access and health economic services for pain management and rare diseases.
SEPTEMBER 2019
Our impact grows with HEOR and global market access services for market-leading Medtech companies in Europe, MENA, and SSA.
MARCH 2011
Prominent consulting firms and universities in the US & Europe outsource their HEOR, global market access projects, and research projects

JANUARY 2008

Our Founder starts consulting at the WHO and Harvard Medical School after receiving his Ph.D. at Northeastern University.

MARCH 2011

Prominent consulting firms and universities in the US & Europe outsource their HEOR, global market access projects, and research projects

JUNE 2015

We strengthen our market access and health economic services for pain management and rare diseases.

SEPTEMBER 2016

Our team expands to support a new Client Charter and clients include Top Pharma and MedTech companies.

APRIL 2018

We introduce the first fully online applied pharmacoeconomic course attended by hundreds in SSA and MENA.

JUNE 2017

Our health economic projects cover various cancers, CVD, rheumatoid arthritis, epilepsy, multiple sclerosis, & HIV/AIDS.

SEPTEMBER 2019

Our impact grows with HEOR and global market access services for market-leading Medtech companies in Europe, MENA, and SSA.

DECEMBER 2021

We further expand the team, and publish the first budget-impact analysis of its kind in the Middle East.

NOVEMBER 2022

Results of our cost-effectiveness analysis on novel treatments continue to go global influencing major stakeholders.

OCTOBER 2022

We publish the world’s first budget-impact analysis on a novel medical device with economic benefits for payors.

...and we keep growing

our growth is driven by our singular focus on accelerating access to innovative healthcare technologies

Directors Digest

Dive-in to Our Insights

The Economic and Clinical Landscape of Haemophilia A: LMIC Perspectives

Introduction Haemophilia A, is a recessive bleeding disorder which causes lifelong bleeding due to reduced or nonexistent circulating factor VIII (FVI

The Cost of Obesity – Can Innovative Healthcare Save Dollars and Lives?

World Obesity Day highlights the serious worldwide problem of increasing obesity rates and the cost of obesity, emphasising the urgent need to tackle

What is Value-Based Healthcare: Enablers and Barriers

Health is an intrinsic value and a precondition for pursuing a good quality of life. Whilst universal healthcare provides equitable health to the popu